📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: FibroGen

1.1 - Company Overview

FibroGen Logo

FibroGen

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of novel therapeutics leveraging CTGF and HIF biology, including Roxadustat, an oral small molecule for anemia in CKD patients on or off dialysis; Pamrevlumab, a human monoclonal antibody in development for metastatic and locally advanced pancreatic cancer and DMD; and FG-3246, a first-in-class fully human ADC targeting CD46 for metastatic castration-resistant prostate cancer and other tumors.

Products and services

  • FG-3246: A fully human ADC architected to target CD46 for metastatic castration-resistant prostate cancer and other tumor types
  • Pamrevlumab: A human monoclonal antibody developed to treat metastatic pancreatic cancer, locally advanced pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD), targeting these indications in ongoing development
  • Roxadustat: An oral small-molecule inhibitor engineered to treat anemia in chronic kidney disease (CKD) patients, indicated for both on-dialysis and not-on-dialysis populations

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to FibroGen

Cephalon Logo

Cephalon

HQ: United States Website
  • Description: Provider of biopharmaceutical discovery, development, and commercialization of medications to improve quality of life worldwide. Founded in 1987, the company delivers first-in-class and best-in-class medicines across several therapeutic areas.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cephalon company profile →
Merck Logo

Merck

HQ: Germany Website
  • Description: Provider of life science, healthcare, and electronics solutions in the U.S. and Canada as EMD Serono, MilliporeSigma, and EMD Electronics. Supplies lab chemicals, solvents, materials, and tools; process solutions for drug development; end-to-end testing, analytics, and manufacturing support; develops medicines and devices for cancer, multiple sclerosis, fertility, and endocrine disorders; and materials/equipment for semiconductors, displays, and surfaces.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Merck company profile →
Athersys Logo

Athersys

HQ: United States Website
  • Description: Provider of an adult-derived, off-the-shelf stem cell therapy platform, MultiStem, for neurological, inflammatory and immune, cardiovascular, and other critical care indications. Conducts clinical trials and programs including MASTERS-2 and TREASURE for stroke, and AMI, PVD, and congestive heart failure.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Athersys company profile →
Bristol Myers Squibb Logo

Bristol Myers Squibb

HQ: United States Website
  • Description: Provider of pharmaceuticals, engaging in the discovery, development, licensing, manufacturing, marketing, distribution and sale of therapies, including cancer immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab); anticoagulant Eliquis (apixaban); oncology treatments Revlimid (lenalidomide) and Sprycel (dasatinib); and autoimmune therapy Orencia (abatacept).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Bristol Myers Squibb company profile →
CohBar Logo

CohBar

HQ: United States Website
  • Description: Provider of mitochondria-based therapeutics as a clinical-stage biotechnology company developing CB4211 for NASH and obesity, showing reduced liver damage biomarkers and glucose levels; CB5138 analogs in preclinical development for IPF and other fibrotic diseases, reducing lung fibrosis and inflammation; and a Mitochondrial Genome Mining platform to discover therapeutic peptides.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CohBar company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for FibroGen

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to FibroGen

2.2 - Growth funds investing in similar companies to FibroGen

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for FibroGen

4.2 - Public trading comparable groups for FibroGen

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to FibroGen

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About FibroGen

What does FibroGen do?

FibroGen is a provider of novel therapeutics leveraging CTGF and HIF biology, including Roxadustat, an oral small molecule for anemia in CKD patients on or off dialysis; Pamrevlumab, a human monoclonal antibody in development for metastatic and locally advanced pancreatic cancer and DMD; and FG-3246, a first-in-class fully human ADC targeting CD46 for metastatic castration-resistant prostate cancer and other tumors.

Who are FibroGen's competitors?

FibroGen's competitors and similar companies include Cephalon, Merck, Athersys, Bristol Myers Squibb, and CohBar.

Where is FibroGen headquartered?

FibroGen is headquartered in United States.

How many employees does FibroGen have?

FibroGen has 1,000 employees 🔒.

When was FibroGen founded?

FibroGen was founded in 2010 🔒.

What sector and industry vertical is FibroGen in?

FibroGen is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for FibroGen

Who are the top strategic acquirers in FibroGen's sector and industry

Top strategic M&A buyers and acquirers in FibroGen's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for FibroGen?

Top strategic M&A buyers groups and sectors for FibroGen include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in FibroGen's sector and industry vertical

Which are the top PE firms investing in FibroGen's sector and industry vertical?

Top PE firms investing in FibroGen's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in FibroGen's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in FibroGen's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in FibroGen's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to FibroGen include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in FibroGen's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for FibroGen?

The key public trading comparables and valuation benchmarks for FibroGen include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for FibroGen for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for FibroGen with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in FibroGen's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for FibroGen with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in FibroGen's' sector and industry vertical?

Access recent funding rounds and capital raises in FibroGen's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for FibroGen